LONDON (Alliance News) - EKF Diagnostics Holdings said Tuesday it is progressing well with the development of a Point of Care platform for Acute Kidney Injury, with testing on clinical samples set to commence in early 2014.
Testing is the next phase in the development which has been undertaken with Carclo Diagnostic Solutions. The platform is being developed as an alternative to standard lateral flow testing as a device to detect Acute Kidney Injury.
The firm said that testing and an assay based on Carclo's micropoc-pro platform should be complete by mid-2014.
Share in EKF were up 1.57% at 33.0 pence per share Tuesday morning. Carclo shares were trading down 4.89% at 331 pence per share.
By Alice Attwood; aliceattwood@alliancenews.com; @AliceAtAlliance
Copyright © 2013 Alliance News Limited. All Rights Reserved.


(Alliance News) - The following is a round-up of earnings reports by London-listed companies, issued on Wednesday and Tuesday and not separately repor...


(Alliance News) - Stock prices in London were lower at midday on Wednesday, as renewed uncertainty about potential talks between the US and Iran weigh...


(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.